Skip to main content
All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for EMERGENT BIOSOLUTIONS · Pharmaceutical company.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Maryland · House · Senate · $40,000.00 income · posted Apr 15, 2026

Official filing document

 Lobbying activity 3
Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, FY2027 NDAA provisions related to biological and chemical defense and access to naloxone.

Defense

National Defense Authorization Act for FY2027, provisions related to biological and chemical defense and access to naloxone.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem